Alzheimer’s disease is the primary cause of age-related dementia. About 15 million people are affected by this neurodegenerative disease worldwide. It has so far not been possible to combat the causes of Alzheimer’s disease. Israeli researchers have now developed a novel approach for treatment. As they report in the journal Angewandte Chemie, the new drug, a molecule made from two nonphysiological amino acids, improves the cognitive abilities of mice with Alzheimer’s and reduces the amyloid plaques in their brains.
Many years before clinical symptoms appear, threadlike deposits of incorrectly folded amyloid â-peptides, known as plaques, form in the brains of Alzheimer’s patients. It was previously assumed that these plaques initiate the degeneration of nerve cells; however, more recent discoveries indicate that smaller, soluble aggregates of the amyloid-forming peptide are the actual cause for the loss of learning and memory functions. These oligomers of about twelve peptide units have a strong toxic effect on nerve cells. The new therapeutic approach taken by researchers working with Ehud Gazit at the University of Tel Aviv aims to block the formation of these toxic oligomers.
A drug molecule was rationally designed that contains an aromatic amino acid and a â-sheet breaker. Aromatic side-groups play a key role in the aggregation of amyloid-forming peptides; the drug should thus bind to the aromatic core of the â-amyloid peptide through its aromatic element. Also, in amyloid aggregates, the proteins adopt the form of â-sheets that are folded like accordions; the drug should thus be a â-breaker, a molecule that prevents proteins from folding into â-sheets. In addition, the molecule must be small so that it can be absorbed by the digestive tract after oral ingestion. It must also not be rapidly degraded by the body and must be nontoxic.
The small dipeptide—a molecule made of two amino acids—developed by Gazit’s team meets all of these requirements: the nonphysiological amino acid á-aminoisobutyric acid acts as a â-breaker, and the second amino acid, D-tryptophan, contains an indole group, which is an effective binder of aromatics. At the same time, D-tryptophan stabilizes the dipeptide, because D-amino acids are broken down more slowly in the body than are the physiological L-amino acids.
When genetically altered mice with Alzheimer’s disease are treated with the dipeptide, their disrupted cognitive functions normalize. A significant decrease in the concentration of amyloid-forming â-peptides and in the size of the plaques was found in the brains of these mice.
Author: Ehud Gazit, Tel Aviv University (Israel), http://www.tau.ac.il/lifesci/departments/biotech/members/gazit/gazit.html
Title: Cognitive-Performance Recovery of Alzheimer's Disease Model Mice by Modulation of Early Soluble Amyloidal Assemblies
Angewandte Chemie International Edition, doi: 10.1002/anie.200802123
Ehud Gazit | Angewandte Chemie
Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute
Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy